Basel Medical Group Ltd Ordinary Shares(BMGL)

Medical - Care Facilities · Singapore, CE

$3.24+0.07 (+2.21%)

Delayed quote: Oct 6, 2026, 9:34 AM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T13:35:49.144Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:35:49.144Z.

Quote observation: 2026-10-06T13:34:50.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 5,072,155
Total debt · period ending 2025-12-31: 7,670,472.0324
Cash · period ending 2025-12-31: 1,043,778.8228
TTM revenue · period ending 2025-12-31: N/A

FMP input reference: 3f32b4356dd318fc5fc0a902c875af90b1a094ceb52f500a6b854293a5898a5a

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BMGL EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

BMGL Competitors' EV/Sales Ratio

BMGL

Basel Medical Group Ltd Ordinary Shares

Current

Market Cap

$5.07M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMNN

Imunon, Inc.

vs BMGL

Market Cap

$5.21M

EV/Sales Ratio

N/A

TTM Avg

21.78x

3Y Avg

80.72x

5Y Avg

86.37x

LIMN

Liminatus Pharma, Inc. Class A Common Stock

vs BMGL

Market Cap

$5.31M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GELS

Gelteq Limited Ordinary Shares

vs BMGL

Market Cap

$4.84M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CALC

CalciMedica, Inc.

vs BMGL

Market Cap

$4.82M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LNAI

Lunai Bioworks Inc.

vs BMGL

Market Cap

$5.33M

EV/Sales Ratio

171.11x

TTM Avg

289.54x

3Y Avg

289.54x

5Y Avg

289.54x

BGMS

Bio Green Med Solution, Inc.

vs BMGL

Market Cap

$4.80M

EV/Sales Ratio

0.54x

TTM Avg

5.83x

3Y Avg

31.22x

5Y Avg

31.22x

ALZN

Alzamend Neuro Inc

vs BMGL

Market Cap

$5.40M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LEXX

Lexaria Bioscience Corp.

vs BMGL

Market Cap

$4.63M

EV/Sales Ratio

6.39x

TTM Avg

29.50x

3Y Avg

46.21x

5Y Avg

38.89x

INBS

Intelligent Bio Solutions Inc.

vs BMGL

Market Cap

$5.54M

EV/Sales Ratio

0.80x

TTM Avg

1.63x

3Y Avg

1.96x

5Y Avg

36.60x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Basel Medical Group Ltd Ordinary Shares (BMGL)	$5.07M	N/A	N/A	N/A	N/A
Imunon, Inc. (IMNN)vs ›	$5.21M	N/A	21.78x	80.72x	86.37x
Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›	$5.31M	N/A	N/A	N/A	N/A
Gelteq Limited Ordinary Shares (GELS)vs ›	$4.84M	N/A	N/A	N/A	N/A
CalciMedica, Inc. (CALC)vs ›	$4.82M	N/A	N/A	N/A	N/A
Lunai Bioworks Inc. (LNAI)vs ›	$5.33M	171.11x	289.54x	289.54x	289.54x
Bio Green Med Solution, Inc. (BGMS)vs ›	$4.80M	0.54x	5.83x	31.22x	31.22x
Alzamend Neuro Inc (ALZN)vs ›	$5.40M	N/A	N/A	N/A	N/A
Lexaria Bioscience Corp. (LEXX)vs ›	$4.63M	6.39x	29.50x	46.21x	38.89x
Intelligent Bio Solutions Inc. (INBS)vs ›	$5.54M	0.80x	1.63x	1.96x	36.60x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics